Favorable cardiac remodeling in response to treatment in obstructive hypertrophic cardiomyopathy: a current appraisal.

IF 1 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Future cardiology Pub Date : 2025-06-01 Epub Date: 2025-06-03 DOI:10.1080/14796678.2025.2501466
Susan Keen, Milind Y Desai
{"title":"Favorable cardiac remodeling in response to treatment in obstructive hypertrophic cardiomyopathy: a current appraisal.","authors":"Susan Keen, Milind Y Desai","doi":"10.1080/14796678.2025.2501466","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertrophic cardiomyopathy is a heterogenous genetic condition caused by myocyte disarray with varying degrees of interstitial fibrosis. Traditional management strategies focused on symptom mitigation and sudden cardiac death prevention among high-risk patients. The only disease-modifying treatments have historically been septal reduction therapy or heart transplantation. However, cardiac myosin inhibitors have emerged as promising novel pharmacotherapies. Emerging evidence indicates that cardiac myosin inhibitors as well as surgical myectomy result in not only symptomatic benefit and reduction in left ventricular outflow tract obstruction, but also positive cardiac remodeling including reduction in left ventricular mass and maximum wall thickness, improved left ventricular diastolic parameters, reduced left atrial volumes, and improved left atrial strain. The long-term durability and clinical significance of these findings require further study. In this article, we will review the existing evidence of favorable reverse remodeling conferred by cardiac myosin inhibitors and surgical myectomy.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"527-537"},"PeriodicalIF":1.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506746/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2025.2501466","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Hypertrophic cardiomyopathy is a heterogenous genetic condition caused by myocyte disarray with varying degrees of interstitial fibrosis. Traditional management strategies focused on symptom mitigation and sudden cardiac death prevention among high-risk patients. The only disease-modifying treatments have historically been septal reduction therapy or heart transplantation. However, cardiac myosin inhibitors have emerged as promising novel pharmacotherapies. Emerging evidence indicates that cardiac myosin inhibitors as well as surgical myectomy result in not only symptomatic benefit and reduction in left ventricular outflow tract obstruction, but also positive cardiac remodeling including reduction in left ventricular mass and maximum wall thickness, improved left ventricular diastolic parameters, reduced left atrial volumes, and improved left atrial strain. The long-term durability and clinical significance of these findings require further study. In this article, we will review the existing evidence of favorable reverse remodeling conferred by cardiac myosin inhibitors and surgical myectomy.

Abstract Image

Abstract Image

对梗阻性肥厚性心肌病治疗的有利心脏重塑:当前评估。
肥厚性心肌病是一种由心肌细胞紊乱和不同程度间质纤维化引起的异质性遗传疾病。传统的治疗策略侧重于缓解高危患者的症状和预防心源性猝死。历史上唯一的疾病改善治疗是间隔缩小治疗或心脏移植。然而,心肌肌球蛋白抑制剂已成为一种有前途的新型药物治疗方法。越来越多的证据表明,心肌肌球蛋白抑制剂和手术切除心肌不仅能改善症状,减少左心室流出道梗阻,而且还能改善心脏重构,包括左心室质量和最大壁厚的减少,左心室舒张参数的改善,左心房容积的减少和左心房应变的改善。这些发现的长期持久性和临床意义有待进一步研究。在这篇文章中,我们将回顾现有的证据表明,心肌肌球蛋白抑制剂和手术切除心肌有利于逆转重塑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future cardiology
Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.80
自引率
5.90%
发文量
87
期刊介绍: Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信